SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?


To: jlib who wrote (71569)5/24/2001 11:57:00 PM
From: jlib  Respond to of 122088
 
"Using Ladenburg’s matrix, HGSI should be worth $64/share, three dollars less than its current valuation. Incyte Genomics, on the other hand, should be trading at $170/share, or a 734% premium to its current price. That's almost as good as GENE. But Genset takes the cake. Using Ladenburg’s valuation metric, Genset should be trading at $83/share, an 1800% premium to its current trading price."

community.metamarkets.com